Dr. Diane Hollenbaugh is a drug discovery scientist and executive with more than 25 years of experience in biologicals research, and discovery and early development. She joined Good Therapeutics in 2019 and transitioned to Bonum Therapeutics following the acquisition by Roche in 2022. Prior to Good, she was Executive Director, Immuno-oncology Discovery at AbbVie where she oversaw the growth of IO efforts, including early discovery and translational science, licensing partnerships, and five discovery projects brought to IND. Prior to AbbVie, she has experience at multiple large and small companies, including BMS, Medarex, FivePrime Therapeutics and Schering-Plough/Merck.
She received her PhD from the California Institute of Technology Division of Chemistry and Chemical Engineering following her BS in Chemistry from the University of Washington.